Table 1. Patient characteristics.
| n | % | True LTFU n (%) | |
|---|---|---|---|
| All | 1431 | 100.0 | 45 (3.1) |
| Clinic | |||
| NHTD | 1057 | 73.9 | 33 (3.1) |
| BMH | 374 | 26.1 | 12 (3.2) |
| Sex | |||
| Male | 929 | 64.9 | 37 (4.0) |
| Female | 502 | 35.1 | 8 (1.6) |
| Age (years) | |||
| Median (25th, 75th percentile) | 32 (29,37) | ||
| <30 | 410 | 28.7 | 20 (4.9) |
| 30–39 | 775 | 54.2 | 19 (2.5) |
| ≥40 | 246 | 17.2 | 6 (2.4) |
| HIV risk factor | |||
| Non IDU | 910 | 63.6 | 16 (1.8) |
| IDU | 521 | 36.4 | 29 (5.6) |
| Latest CD4 count (/μl) | |||
| Median (25th, 75th percentile) | 371 (250, 512) | ||
| <350 | 655 | 45.8 | 32 (4.9) |
| ≥350 | 776 | 54.2 | 13 (1.7) |
| Latest plasma viral load (copies/ml) | |||
| <500 | 1354 | 94.6 | 32 (2.4) |
| ≥500 | 76 | 5.3 | 13 (17.1) |
| Missing | 1 | 0.1 | 0 (0.0) |
| HBV co-infection a | |||
| Yes | 187 | 13.1 | 5 (2.7) |
| No | 1226 | 85.7 | 39 (3.2) |
| Missing | 18 | 1.3 | 1 (5.6) |
| HCV co-infection b | |||
| Yes | 617 | 43.1 | 29 (4.7) |
| No | 677 | 47.3 | 12 (1.8) |
| Missing | 137 | 9.6 | 4 (3.0) |
| History of tuberculosis | |||
| Yes | 242 | 16.9 | 9 (3.8) |
| No | 1189 | 83.1 | 36 (3.0) |
| Duration of ART at baseline (months) | |||
| Median (25th, 75th percentile) | 5 (2, 9) | ||
| <6 | 460 | 32.2 | 14 (3.0) |
| 6–11 | 380 | 26.6 | 9 (2.4) |
| ≥12 | 585 | 40.9 | 21 (3.6) |
| Missing | 6 | 0.4 | 1 (16.7) |
n; number of participants,
LTFU; loss to follow-up,
NHTD; National Hospital of Tropical Diseases,
BMH; Bach Mai Hospital,
IDU; injection drug use
aHBV co-infection was assessed by HBV antigen positivity at registration
bHCV co-infection was assessed by HCV antibody positivity at registration.